There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases.
Introduction
The World Health Organization (WHO) estimates that about one billion people worldwide are overweight or obese and at least 300 million are obese [1] . On the basis of evidence provided by several research studies, it is now generally accepted that obesity increases the risk for type 2 diabetes, cardiovascular disease, hypertension, and many other major illnesses including cancer, and contributes to decreased longevity [1, 2] . Because 90% of individuals with adult-onset diabetes are overweight or obese, an epidemic of type 2 diabetes is paralleling the worldwide epidemic of obesity [3 ] . In general, currently available nonsurgical interventions for obesity have demonstrated rather modest efficacy in clinical trials and limited effectiveness in clinical practice [4] [5] [6] . NIH guidelines recommend that diet and exercise be part of all efforts to treat obesity [7] . However, the recommended lifestyle therapies seem to provide very modest long-lasting success for obese individuals making efforts to lose weight. About half of the weight lost with the help of lifestyle therapies is regained at 1 year, and after 3-5 years, only one in five maintains a clinically meaningful weight loss [4] . A recent systematic review concluded that dietary and lifestyle therapies lead to an average weight loss of less than 5 kg after 2-4 years [8] .
Although it may be possible to achieve more substantial weight loss with intensive lifestyle interventions delivered in structural clinical environments [9] , such interventions are not available to most obese individuals and health providers due to limited accessibility and affordability. Whereas successful bariatric surgery administered by expert surgeons has been demonstrated to achieve significant weight loss [10, 11] , given the current costs and associated risks, presently this is not a viable therapeutic option for the majority of obese patients.
According to FDA, antiobesity drugs are indicated for patients with a body mass index (BMI) of at least 30 kg/m 2 and also for those with a BMI of at least 27 kg/m 2 in the presence of obesity-related diseases or risk factors such as type 2 diabetes and hypertension [7] . Because most obese patients are insufficiently successful in their attempts to lose weight with diets, exercise and lifestyle modifications, antiobesity drugs have a role in obesity management and can enhance adherence to weight loss programmes [12] . Further, drug therapy is presumably easier to deliver in real life settings, given that primary care physicians are the primary providers of obesity treatment [13] .
Limitations of currently available antiobesity drugs
The major limitation of pharmacotherapy is the rather modest efficacy of the currently approved drugs. Two drugs -sibutramine and orlistat -are currently approved for long-term treatment of obesity. In randomized controlled trials (RCTs), these two drugs have modest efficacywith anaverageweightloss of4.2 kgforsibutramine and 2.9 kg for orlistat after 1-year treatment, in excess of the weight loss achieved by diet and lifestyle management [14] . Further, less than 10% of patients prescribed these drugs still take them at 1 year [6] . Whereas factors such as tolerability and affordability might also be possible reasons, failure of these drugs in real life settings is most likely attributable to the fact that obese patients expect to shed an average of about 25% of their body weight with 1 year treatment [15] and the efficacy of these drugs falls far below the expectations of the patients.
Although considerable knowledge has been accumulated over the years regarding the biological basis for obesity and various neuronal and peripheral entities that are involved in regulation of food intake and energy homeostasis [16 ] , scientists have not enjoyed much success in translating such knowledge into finding better drug therapies. Numerous drug candidates with novel mechanisms of action that targeted new sites in the central nervous system as well as the peripheral organs have either not achieved clinically meaningful efficacy in large randomized clinical trials (examples include recombinant leptin [17] and NPY5R antagonist, MK-0557 [18] ) or failed to meet the safety expectation of regulatory authorities (e.g. CB1 receptor antagonist, rimonabant [19] [20] [21] ).
Possible reasons for failure of antiobesity drugs
Failure of new drug candidates in human experiments, after initial demonstration of projected effects in animal models, could be related to several factors. First, because humans do not live in environments in which food intake is carefully controlled and are subject to various external stimuli for food ingestion, more robust drug effects might be needed in humans than in animals to achieve therapeutic benefits. Secondly, because efficacy in humans is assessed in long-term clinical trials these days, failure of newer drugs could be related to the possibility that endogenous compensatory mechanisms are activated and overcome pharmaceutical manipulations. Thirdly, because numerous neuronal and peripheral pathways seem to be involved in food intake and energy regulation, it is conceivable that human body bypasses pharmacologically blocked or otherwise manipulated pathways and reverts the person's food intake and energy balance to the previous state by bolstering other pathways.
Whereas obesity is diagnosed using a weight and height calculation, the causes of obesity vary among persons. Further, even when the basis for obesity is primarily biological, the endogenous factors contributing to obesity might not be the same in all affected individuals. A drug specifically targeting one pathway might not achieve a robust therapeutic effect in an obese individual if this specific person's obesity is primarily related to the actions of another pathway, neurotransmitter, neuropeptide, or another biological moiety of importance to weight regulation on which this specific drug does not have major effect. A recent meta-analysis has shown that 54-55% of obese patients treated with sibutramine or orlistat achieve 5% weight loss over a year compared to 27-33% achieving the same with placebo treatment [14] . When the proportions of patients losing at least 10% weight are examined, the figures are 26-28% for sibutramine or orlistat vs. 10-14% for placebo. This heterogeneity of weight change (often taken to be equivalent to heterogeneity of response, but not strictly so [22] ) is not unique to antiobesity drugs. When Spear et al. [23] examined 14 therapeutic areas, the mean change after taking a major drug was 51.5% with high rates for COX-2 inhibitors used for arthritis and rates as low as 25% for oncology drugs. Sex, age, ethnicity, diet, illness severity, concomitant medications, alcohol and tobacco consumption, cultural and environmental factors, and physiological factors could partly explain the heterogeneity. In many instances though, such heterogeneity cannot be readily explained by the above-mentioned variables, especially in the case of drugs working on the neuronal pathways. In the treatment of essential hypertension, it is well recognized that, although the diagnosis is made on the basis of specified cutoffs for systolic and diastolic blood pressure readings, the primary factors contributing to hypertension -vascular, renal, hormonal, dietary and lifestyle -might be different for different patients, and as such, diuretic drugs work better for some patients and beta-blockers work better for different patients. Many hypertensive patients are treated today with combinations of drugs with different mechanisms of action and working on different sites to achieve a therapeutic response of a clinically meaningful magnitude. Combination therapies are also commonly used in the treatment of diabetes, cancer and many other major illnesses.
Pros and cons of combination therapy
Putative advantages [24] of combination-drug therapies are the following: efficacy could be enhanced via additive or synergistic effects; they could promote endogenous synergies; drugs with different pharmacodynamic actions and exerting effects on multiple pathways could overcome the natural compensatory mechanisms involved in energy homeostasis, and thereby prevent or delay the formation of plateau during weight loss effort; combination of lower doses could reduce the burden of adverse effects; a combination of drugs with known dissimilar side-effects (e.g. a drug that is associated with insomnia combined with a drug with an increased incidence of drowsiness) could improve tolerability.
Possible risks include the following: there might be an increase in the incidence of some adverse effects; rare, but serious, adverse events that are not picked up during a clinical drug development process might surface after several thousand patients are exposed to the drugs in clinical practice, though this is true of single-drug as well as combination-drug therapy.
History of combination-drug therapy for obesity
Combination-drug therapies have been tested for treatment of obesity. In the early nineties, a combination of ephedrine/caffeine (20 mg/200 mg) demonstrated more weight loss than ephedrine (20 mg), caffeine (200 mg) or placebo, all given three times a day over 24 weeks in obese patients who also received dietary intervention [25] . Ephedrine in the form of dietary supplements was banned in the US in 2004 due to concerns of the FDA regarding cardiovascular and cerebrovascular adverse events.
In the mid-nineties, the use of a so-called 'fen-phen' combination (phentermine and fenfluramines) therapy surged tremendously following publication of a series of studies. In a preliminary study [26] that examined the combination therapy, lower doses of the individual components (fenfluramine 30 mg/day and phentermine 15 mg/day) administered together achieved about the same weight loss (8.4 kg) as phentermine 30 mg/day (10.0 kg) and fenfluramine 60 mg/day (7.5 kg) over 24 weeks. In a subsequent RCT [12] , after 6 weeks of lifestyle intervention, 121 obese patients were treated with the combination of fenfluramine 60 mg and phentermine 15 mg or placebo for an additional 28 weeks. Patients receiving the combination-drug therapy lost 14.2 kg, whereas those treated with placebo lost 4.6 kg. Use of antiobesity drugs in general and the fen-phen combination, in particular, increased dramatically after release of dexfenfluramine in 1996. In early 1997 when antiobesity drug use was at its peak, 2.5 million Americans were using these drugs, a four-fold increase from the two prior years [13] . Later that year, fenfluramine and dexfenfluramine were withdrawn from markets due to reports of valvular heart disease. Concerns about primary pulmonary hypertension were also present.
Combination antiobesity drugs currently in development
At the time of submission of this manuscript, two combination-drug therapies -bupropion þ naltrexone and topiramate þ phentermine -are in late-stage clinical investigations for weight reduction in obese nondiabetic and diabetic patients. Summary results of several phase III trials of these two combination-drug therapies are expected to be released in the second half of 2009. Another combination therapy -bupropion þ zonisamide -is being tested in a phase IIb trial; results of this trial are expected in the third quarter of 2009. Pramlintide þ leptin is another combination therapy for which a proofof-concept study has been completed. Finally, PYY 3-36 and GLP-1 are also being tested in combination in early phase trials.
Naltrexone R bupropion
Bupropion is marketed for treatment of depression as well as nicotine addiction. The drug has been demonstrated to have weight-loss efficacy in obese patients in three RCTs [27] . Naltrexone, an opioid receptor antagonist, marketed to treat alcoholism and opioid addiction, attenuates caloric intake in animals [28] , but failed to promote clinically meaningful weight loss in humans in randomized trials [29] [30] [31] . The basis for combining these drugs comes from the observations that addition of naltrexone to bupropion enhanced the firing of hypothalamic pro-opiomelanocortin (POMC) neurons more so than when bupropion was administered alone in mice [32 ] . It is known [16 ] that activation of POMC neurons results in release of the appetite-suppressing and catabolic neuropeptide, a-melanocyte-stimulating hormone (a-MSH). In a 16-week proof-of-concept study, bupropion þ naltrexone (NB, 300 mg/50 mg) combination was shown to cause more weight loss in obese patients than bupropion (300 mg), naltrexone (50 mg), or placebo [32 ] . Because nausea was a frequent adverse effect in patients receiving naltrexone or the combination, lower doses of naltrexone were tested in a subsequent 24-week, phase IIb trial. In this study, all three doses of naltrexone (48, 32, and 16 mg) combined with bupropion 400 mg/day resulted in significant weight loss (4.3, 5.4, and 5.4%, respectively) at 24 weeks, all doses being more effective than placebo (0.8% weight loss) with better tolerability for the lower doses [33] . On this foundation, the sponsor started four phase III trials (NB-301, NB-302, NB-303 and NB-304) investigating this combination for weight loss in obese patients with or without type 2 diabetes. In three trials, the investigational drug is a fixed-dose combination of bupropion 360 mg/naltrexone 32 mg, whereas one trial also compares this combination to bupropion 360 mg/ naltrexone 16 mg. Summary results have been released at the end of 2008 for the NB-302 study [33] . This was a 56-week RCT in which 793 obese patients received the naltrexone þ bupropion combination therapy or placebo together with an intensive behavior modification intervention. Those receiving the naltrexone þ bupropion combination therapy achieved 9.3% weight loss compared with 5.1% for the placebo group. Twice as many patients receiving the naltrexone þ bupropion combination therapy lost 10% of their body weight relative to placebo (41.5 vs. 20.2%). The most common adverse effect, nausea, led to discontinuation of 4.6% of the naltrexone þ bupropion patients.
Results of three ongoing phase III trials are expected to be released in the second half of 2009 [33] . The NB-301 trial enrolled 1740 obese patients who were randomized to receive one of two active drug therapies that combined bupropion 360 mg with naltrexone 32 mg or 16 mg, or placebo. The NB-303 trial is also a 56-week RCT that compares bupropion 360 mg þ naltrexone 32 mg with placebo; the naltrexone þ bupropion patients who have not achieved at least 5% weight loss after 28 weeks are rerandomized to receive a higher naltrexone þ bupropion dose (bupropion 360 mg þ naltrexone 48 mg) or remain on the original dose. The NB-304 trial enrolled obese patients with type 2 diabetes; weight loss is the primary outcome measure [33] .
Zonisamide R bupropion
Zonisamide, marketed as an antiepileptic, was found to promote weight loss in obese patients in a randomized controlledtrial [34 ] .Asmallstudyfoundthatacombination of zonisamide and bupropion led to more weight loss than zonisamide alone [35] . Subsequently, in a 24-week RCT, zonisamide þ bupropion (ZB, 400 mg/300 mg) achieved more weight loss than zonisamide (400 mg), bupropion (300 mg), or placebo (À9.2, À6.6, À3.6, and À0.4%, respectively) [36] . In a later phase IIb trial (ZB-201) that compared various doses of bupropion and zonisamide in the combination, all six different ratio combinations achieved significantly greater weight loss than placebo, with zonisamide 360 mg/bupropion 360 mg showing the greatest efficacy (8.6% for zonisamide þ bupropion vs. 1.1% for placebo) [33] . Headache, nausea, insomnia, anxiety and dry mouth were the most common adverse effects. Another phase IIb RCT (ZB-202), results of which are expected in the later part of 2009, compares two doses of zonisamide þ bupropion (Z360 þ B360 or Z120 þ B360) against the individual constituents and placebo [33] .
Topiramate R phentermine
Phentermine is the most prescribed antiobesity drug in the US [13, 37] , whereas it was withdrawn from the European markets a few years ago. In the US, it is indicated for short-term treatment of obesity, although it is generally prescribed for longer periods by physicians [13] . Topiramate, a drug with multiple pharmacological mechanisms of action and marketed for treatment of epilepsy and prevention of migraine, has been shown to promote weight loss in obese patients in numerous studies, but an unacceptably high incidence of neuropsychiatric adverse effects has limited its further development for treatment of obesity [38] [39] [40] [41] [42] . In a 24-week RCT involving 200 obese patients, Gadde et al. [43] examined the weight-loss efficacy of topiramate þ phentermine (100 mg/15 mg) in comparison to topiramate (100 mg), phentermine (15 mg), or placebo. The combination treatment led to weight loss of 11.4 kg, which was significantly greater than weight loss achieved with topiramate (6.6 kg), phentermine (5.3 kg), or placebo (2.2 kg). In a subsequent multicenter RCT with seven treatment arms (OB-301 trial), 756 obese patients were randomly assigned to placebo, or higher or lower doses of phentermine (15 mg, 7.5 mg), topiramate (92 mg, 46 mg), or the combination (15 mg/92 mg, 7.5 mg/46 mg) for 28 weeks [44] . Higher-dose combination therapy led to 9.2% weight loss compared with 6.4% for higher-dose topiramate, 6.1% for higher-dose phentermine, and 1.7% for placebo. Lower-dose combination therapy was also effective with 8.5% weight loss relative to lower-dose topiramate (5.1%), phentermine (5.5%), and placebo (1.7%). Two 1-year phase III trials (OB-302 and OB-303) are underway, summary results of which are expected in the later half of 2009. In addition, a 56-week RCT examined the efficacy of topiramate þ phentermine in 130 obese patients with type 2 diabetes [45] . Patients treated with topiramate þ phentermine achieved 9.4% weight loss compared with 2.7% with placebo. Haemoglobin A1c decreased by 1.6% in the drug group vs. 1.1% in the placebo group. Most common adverse effects of the topiramate þ phentermine combination include paresthesia, nausea, dry mouth, constipation, dizziness and insomnia. Warnings in the product information brochure for topiramate include the risks of neuropsychiatric adverse events and rare occurrence of acute myopia with secondary angle closure glaucoma, and metabolic acidosis (decreased serum bicarbonate levels). There have been recent studies of increased incidence of congenital malformations among infants whose epileptic mothers received topiramate alone or in combination with other antiepileptic drugs [46] .
Pramlintide R leptin
Pramlintide, an amylin analog, marketed for treatment of diabetes, causes mild-to-modest weight loss [47] . Leptin, an adipocyte-derived hormone, causes modest weight loss in humans [17] . In a proof-of-concept study [48 ] , 177 overweight or obese patients were first treated with pramlintide and 40% energy-restricted diet for 4 weeks. After 21% of patients were withdrawn (9% due to insufficient weight loss), the remaining patients were randomized to pramlintide 360 mg, leptin 5 mg, or the combination for 20 weeks. Weight change during the 20-week randomized period was À9.9 kg for the combination, À7.2 kg for pramlintide, and À7.2 kg for leptin. There was no placebo comparison. Each drug had to be administered separately twice a day needing four daily subcutaneous injections. Adverse effects include nausea and injection site irritation.
Glucagon-like peptide-1 R PYY 3-36
Glucagon-like peptide-1 (GLP-1) is a gut hormone secreted rapidly in response to food. GLP-1 inhibits glucagon secretion and gastric emptying and stimulates glucose-dependent insulin secretion, thereby lowering blood glucose [49] . Peripheral administration of GLP-1 has been shown to decrease food intake in obese diabetic patients [50] . Exendin-4 (Exenatide), a naturally occurring GLP-1 agonist, administered subcutaneously twice a day, has led to mild-to-moderate weight loss in patients with type 2 diabetes [51] . Peptide YY (PYY 3-36 ) is a gut peptide hormone that is secreted in response to food ingestion [52] . Intravenous infusion of PYY 3-36 has been shown to reduce food intake by about 30% over a day in a small group of obese and lean patients [53] . A recent news study described a reduction in food intake after administration of the combination of oral GLP-1 2 mg and PYY 3-36 1 mg, one tablet each, although there was no synergistic effect [54] .
Phentermine R L-5-hydroxytryptamine R carbidopa
A recent publication [55] reported short-term weight loss in patients treated in a physician's office with a combination of high-dose phentermine and L-5-hydroxytryptophan (5-HTP), a precursor of serotonin, along with carbidopa, which inhibits an enzyme called aromatic L-amino acid decarboxylase, and thereby prevents the metabolism of 5-HTP in the liver with resultant increase in blood levels of 5-hydroxy-tryptamine (5-HT or serotonin). For most patients, the starting daily doses were phentermine 40 mg, 5-HTP 15 mg, and carbidopa 15 mg, with phentermine given in two divided doses and the other two in three divided doses. By week 1, the mean daily doses were about 55 mg for phentermine and 22 mg for 5-HTP, whereas carbidopa dose remained at 15 mg. Author reported that patients who were most compliant achieved average weight losses of 2.4 kg after 1 week and 4.6 kg (4.7%) after 4 weeks. As this was not a controlled clinical trial, one would not know whether this threedrug combination would have achieved more weight loss than phentermine alone at 55 mg/day, which is considerably higher than the recommended dose. There were no echocardiographic assessments reported. Because carcinoid heart disease is thought to be a consequence of hyperserotoninemia [56] and the withdrawal of serotonergic antiobesity drugs, fenfluramine and dexfenfluramine, was related to emergence of carcinoid-type valvular heart disease with long-term exposure, clinicians should be cautious about administering drugs that raise 5-HT levels in the peripheral circulation for lack of adequate safety data from scientific studies. No RCTs have been conducted for examining the efficacy and safety of this combination therapy.
Conclusion
Among the various combination-drug therapies that are being investigated for treatment of obesity and related disorders, two combinations -bupropion þ naltrexone and topiramate þ phentermine -are in the late stages of clinical development. Whereas results of several ongoing phase III trials are expected to be available in the later part of 2009, available data from the completed studies indicate that these combination therapies achieve significantly more weight loss than individual constituents. These two combination therapies appear to be generally tolerated well, although it is not possible to comment on the safety until larger data sets become available. A major limitation of this review paper is that most of the data for the emerging combination drug therapies presented here have come from meeting abstracts, press releases and financial reports and not from peer-reviewed scientific publications.
